新芝生物
(430685)
| 流通市值：8.95亿 | | | 总市值：14.95亿 |
| 流通股本：5479.11万 | | | 总股本：9151.60万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 184,992,029.22 | 142,237,727.06 | 160,487,708.6 | 154,428,367.12 |
| 应收票据及应收账款 | 9,539,460.1 | 11,690,732.13 | 11,772,940.27 | 7,236,276.98 |
| 其中：应收票据 | 788,566.3 | 608,145.52 | 837,813.24 | 719,833.55 |
| 应收账款 | 8,750,893.8 | 11,082,586.61 | 10,935,127.03 | 6,516,443.43 |
| 应收款项融资 | 206,799.91 | 52,733.6 | - | - |
| 预付款项 | 3,981,399.07 | 3,274,854.48 | 3,956,330.38 | 4,412,524.08 |
| 其他应收款合计 | 711,931.85 | 637,110.3 | 1,157,680.23 | 1,102,508.27 |
| 存货 | 43,130,264.79 | 42,420,605.49 | 47,777,249 | 49,726,654.89 |
| 其他流动资产 | 2,134,745.39 | 1,509,605.8 | 2,398,735.22 | 2,630,957.49 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 399,756,000.25 | 424,831,087.35 | 397,697,796.51 | 426,557,543.14 |
| 非流动资产: | | | | |
| 长期股权投资 | 0 | 0 | 0 | - |
| 其他非流动金融资产 | - | - | 40,176,216.28 | - |
| 固定资产 | 34,745,343.61 | 35,730,684.34 | 42,606,391.99 | 43,114,445.37 |
| 在建工程 | 124,123,012.92 | 111,996,862.8 | 89,952,119.55 | 84,037,860.99 |
| 使用权资产 | 6,207,839.71 | 1,974,652.68 | 3,834,337.21 | 4,676,547.16 |
| 无形资产 | 21,100,431.26 | 21,632,924.46 | 21,849,876.24 | 21,653,229.5 |
| 商誉 | 6,868,485.01 | 6,868,485.01 | 6,868,485.01 | 6,868,485.01 |
| 长期待摊费用 | 1,076,232.83 | 1,333,882.16 | 1,591,531.5 | 1,805,548.75 |
| 递延所得税资产 | 930,700.17 | 1,015,828.19 | 2,329,056.45 | 2,216,304.68 |
| 其他非流动资产 | 43,610,597 | 42,299,108.26 | 1,710,835.9 | 1,710,835.9 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 238,662,642.51 | 222,852,427.9 | 210,918,850.13 | 166,083,257.36 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 638,418,642.76 | 647,683,515.25 | 608,616,646.64 | 592,640,800.5 |
| 流动负债: | | | | |
| 短期借款 | 0 | 0 | 0 | - |
| 应付票据及应付账款 | 35,466,332.3 | 32,923,285.89 | 20,505,894.89 | 25,224,769.53 |
| 应付账款 | 35,466,332.3 | 32,923,285.89 | 20,505,894.89 | 25,224,769.53 |
| 合同负债 | 9,332,714.21 | 9,093,113.62 | 12,776,474.25 | 9,624,938.56 |
| 应付职工薪酬 | 6,226,481.95 | 16,972,602.4 | 12,388,848.55 | 8,897,729.71 |
| 应交税费 | 2,738,814.14 | 6,834,519.96 | 3,414,933.91 | 1,233,039.75 |
| 其他应付款合计 | 206,269.74 | 354,458.25 | 2,271,834.55 | 287,598.21 |
| 一年内到期的非流动负债 | 1,913,129.77 | 1,372,413.45 | 3,230,557.56 | 3,191,342.35 |
| 其他流动负债 | 1,344,227.28 | 1,249,774.51 | 1,183,082.63 | 923,999.21 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 57,227,969.39 | 68,800,168.08 | 55,771,626.34 | 49,383,417.32 |
| 非流动负债: | | | | |
| 长期借款 | 0 | 0 | 0 | - |
| 租赁负债 | 3,685,778.5 | 180,450.2 | - | 756,605.82 |
| 递延所得税负债 | 2,134.47 | 7,803.08 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 3,687,912.97 | 188,253.28 | - | 756,605.82 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 60,915,882.36 | 68,988,421.36 | 55,771,626.34 | 50,140,023.14 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 91,515,941 | 91,515,941 | 91,515,941 | 91,515,941 |
| 资本公积 | 352,510,679.01 | 352,510,679.01 | 352,446,141.5 | 352,285,962.96 |
| 减:库存股 | 28,235,967.38 | 28,235,967.38 | 28,235,967.38 | 28,235,967.38 |
| 盈余公积 | 31,802,029.18 | 31,802,029.18 | 28,934,321.39 | 28,934,321.39 |
| 未分配利润 | 98,117,550.19 | 91,615,965.43 | 74,509,077.02 | 65,916,808.03 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 545,710,232 | 539,208,647.24 | 519,169,513.53 | 510,417,066 |
| 少数股东权益 | 31,792,528.4 | 39,486,446.65 | 33,675,506.77 | 32,083,711.36 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 577,502,760.4 | 578,695,093.89 | 552,845,020.3 | 542,500,777.36 |
| 负债和股东权益合计 | 638,418,642.76 | 647,683,515.25 | 608,616,646.64 | 592,640,800.5 |
| 公告日期 | 2025-04-28 | 2025-04-21 | 2024-10-29 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |